Efficacy of daptomycin in the treatment of enterococcal endocarditis: A 5 year comparison with conventional therapy

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 6, 2014, Pages 1669-1674

  Ceron I ^a   Munoz P ^a,b,c,d   Marin M ^a,c,d   Segado, A ^a   Roda, J ^a   Valerio, M ^a,d   Bouza, E ^a,b,c,d  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Antimicrobial therapy; Enterococcus; Infective endocarditis; Outpatient parenteral therapy

Indexed keywords

AMPICILLIN; CEFTRIAXONE; DAPTOMYCIN; GENTAMICIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DISEASE DURATION; DRUG EFFICACY; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECIUM; FEMALE; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; LENGTH OF STAY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; RETROSPECTIVE STUDY; COMORBIDITY; COMPLICATION; CROSS INFECTION; DRUG COMBINATION; DRUG SUBSTITUTION; ENDOCARDITIS, BACTERIAL; ENTEROCOCCUS; GRAM POSITIVE INFECTION; MICROBIOLOGY; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COMORBIDITY; CROSS INFECTION; DAPTOMYCIN; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; ENDOCARDITIS, BACTERIAL; ENTEROCOCCUS; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84903905043     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku004     Document Type: Article

References (20)

1. Murdoch DR, Corey GR, Hoen B et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med 2009; 169: 463-73.
2. Habib G, Hoen B, Tornos P et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J 2009; 30: 2369-413.
3. Gould FK, Denning DW, Elliott TS et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2012; 67: 269-89.
4. Li JS, Sexton DJ, Mick N et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000; 30: 633-8.
5. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-first Informational Supplement M100-S21. CLSI, Wayne, PA, USA, 2010.
6. Gallagher JC, Perez ME, Marino EA et al. Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients. Pharmacotherapy 2009; 29: 792-9.
7. Huang YT, Liao CH, Teng LJ et al. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan. Clin Microbiol Infect 2008; 14: 124-9.
8. Davlieva M, Zhang W, Arias CA et al. Biochemical characterization of cardiolipin synthase mutations associated with daptomycin resistance in enterococci. Antimicrob Agents Chemother 2013; 57: 289-96.
9. Hall AD, Steed ME, Arias CA et al. Evaluation of standard-and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2012; 56: 3174-80.
10. Poutsiaka DD, Skiffington S, Miller KB et al. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect 2007; 54: 567-71.
11. Mave V, Garcia-Diaz J, Islam Tet al. Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid? J Antimicrob Chemother 2009; 64: 175-80.
12. Arias CA, Torres HA, Singh KV et al. Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster. Clin Infect Dis 2007; 45: 1343-6.
13. Enoch DA, Phillimore N, Karas JA et al. Relapse of enterococcal prosthetic valve endocarditis with aortic root abscess following treatment with daptomycin in a patient not fit for surgery. J Med Microbiol 2010; 59: 482-5.
14. Kanafani ZA, Federspiel JJ, Fowler VG Jr. Infective endocarditis caused by daptomycin-resistant Enterococcus faecalis: a case report. Scand J Infect Dis 2007; 39: 75-7.
15. Segreti JA, Crank CW, Finney MS. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy 2006; 26: 347-52.
16. Levine DP, Lamp KC. Daptomycin in the treatment of patients with infective endocarditis: experience from a registry. Am J Med 2007; 120 Suppl 1: S28-33.
17. Dohmen P, Guleri A, Petrosillo R et al. Daptomycin for the treatment of infective endocarditis: results from European Cubicin Outcomes Registry and Experience (EU-CORE). In: Abstracts of the Twentieth European Congress of Clinical Microbiology and Infectious Diseases, Vienna, 2010. Abstract O511, p. 83. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
18. Caron F, Kitzis MD, Gutmann L et al. Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium. Antimicrob Agents Chemother 1992; 36: 2611-6.
19. Schutt AC, Bohm NM. Multidrug-resistant Enterococcus faecium endocarditis treated with combination tigecycline and high-dose daptomycin. Ann Pharmacother 2009; 43: 2108-12.
20. Pankey G, Ashcraft D, Patel N. In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin. Antimicrob Agents Chemother 2005; 49: 5166-8.